/data/photo/2024/07/30/66a8e1cf0ba0a.jpg)
PT Esa Medika Mandiri Tbk. (EMMI) akan melakukan IPO dengan: - Kisaran harga penawaran: Rp446–Rp515 per saham - Jumlah saham ditawarkan: hingga 522,86 juta saham baru (sekitar 30% dari modal ditempatkan dan disetor penuh) - Potensi dana yang dihimpun: hingga Rp269,27 miliar - Alokasi saham untuk ESA (Employee Stock Allocation): hingga 52,29 juta saham (10% dari saham ditawarkan) - Struktur pemegang saham pasca-IPO diproyeksikan: publik sekitar 27%; sisanya tetap di pemegang kendali keluarga Widjaja - Penggunaan dana IPO: memperkuat struktur permodalan, bayar sebagian pokok pinjaman, belanja modal, dan modal kerja - Waktu penting: masa bookbuilding 22–24 Juni 2026; persetujuan efektif OJK 30 Juni 2026; masa penawaran umum 2–6 Juli 2026; pencatatan di BEI diperkirakan 8 Juli 2026 - Struktur permodalan proforma (setelah IPO): total saham beredar menjadi 1,74 miliar; pemegang utama termasuk keluarga Widjaja (berenang antara enam individu inti) dan ESA + publik (27%) - Penjamin pelaksana emisi: BRI Danareksa Sekuritas dan Ina Sekuritas Indonesia (full commitment)
Summary: - PT Esa Medika Mandiri Tbk (EMMI) plans an IPO on the Indonesia Stock Exchange (BEI) with ticker EMMI, targeting Wednesday, July 8, 2026. - IPO details: 522.85 million new shares at Rp 50 nominal each, representing up to 30% of issued and paid-up capital. IPO price range: Rp 446–515 per share. - Potential funds raised: up to Rp 269.27 billion if all new shares are fully subscribed; 10% of proceeds earmarked for an employee stock allocation (ESA). - Underwriters/lead managers: PT BRI Danareksa Sekuritas and PT INA Sekuritas Indonesia. - Business profile: Medical device distributor focused on laboratory, pharmaceutical, and hospital equipment; provides integrated solutions for health facilities, including operating rooms and ICUs. Also holds exclusive distribution rights for several global medtech brands. - Growth plan: Expand into consumables (e.g., surgical sutures) and pursue joint ventures with global partners to diversify revenue and boost recurring income, reducing reliance on non-recurring procurement projects. - Experience and reach: Over 25 years in operation; serves more than 200 hospitals and health institutions in Indonesia, with a customer base dominated by government hospitals and institutional facilities.
Summary: - PRDL (Prodia Diagnostic Line Tbk) akan melakukan IPO di Bursa Efek Indonesia pada Juli 2026. - Menawarkan maksimal 522,9 juta saham baru, sekitar 30% dari modal ditempatkan dan disetor penuh setelah IPO. - Kisaran harga penawaran: Rp100–Rp120 per saham. - Potensi dana yang dapat dihimpun: hingga Rp62,75 miliar. - Penggunaan dana: memperkuat struktur permodalan (sekitar Rp35,67 miliar untuk pelunasan fasilitas kredit ke BCA dan Bank Pan Indonesia), belanja modal sekitar 28,92% (mesin/kalibrasi, kendaraan operasional, software, relayout produksi, AHU LAB biomolekuler), dan modal kerja sekitar 8,51% (bahan baku, riset & pengembangan, pemasaran). - Masa penawaran awal (bookbuilding): 18–23 Juni 2026. Tanggal efektif OJK diperkirakan 29 Juni 2026. - Masa penawaran umum: 1–7 Juli 2026; penjatahan: 7 Juli 2026; distribusi elektronik: 8 Juli 2026; pencatatan di BEI: 9 Juli 2026. - Penjamin pelaksana emisi: PT Sucor Sekuritas. - Program alokasi saham untuk karyawan (ESA): hingga 36,6 juta saham (sekitar 7% dari total yang ditawarkan) dengan harga pelaksanaan sama dengan harga IPO.
Prodia Diagnostic Line berencana melakukan IPO dengan kode saham PRDL. Perusahaan produksi dan pengolahan alat kesehatan diagnosis ini menawarkan maksimal 522,90 juta saham–setara 30% dari modal ditempatkan dan disetor penuh setelah IPO–termasuk program ESA sebesar 36,60 juta saham (7% dari saham ditawarkan). Rentang harga penawaran awal ditetapkan Rp100–Rp120 per saham, sehingga potensi dana segar maksimum sekitar Rp62,74 miliar. Penggunaan dana IPO: - Sekitar Rp33,66 miliar untuk pelunasan pokok fasilitas kredit (setelah dikurangi biaya emisi), khususnya kepada BCA dan Bank Panin. - Sekitar 28,92% untuk belanja modal (capex). - Sekitar 8,51% untuk modal kerja. Masa bookbuilding berlangsung 18–23 Juni 2026. IPO diawaki oleh PT Sucor Sekuritas sebagai penjamin pelaksana emisi.
Summary: - Company: PT Niramas Utama Tbk (JELI) also known as INACO. - IPO date: Target listar di BEI pada 7 Juli 2026. - Offering: Up to 350 million new shares (about 25.93% of diluted equity) at Rp 900–Rp 1,120 per share. - Potential fresh funds: Up to Rp 392 miliar. - Use of proceeds (by allocation): - ~51.04% to inject capital into subsidiary PT NPS (equity) for capex to expand gummy candy and jelly production to meet domestic and export demand. - ~18.36% for general capex (production equipment, storage, logistics improvements). - ~10.63% to repay short-term debt (Bank Mandiri KMK 1 & KMK 2), reducing debt from Rp 94 billion (as of 31 Mar 2026) to about Rp 54 billion post-use. - ~19.97% for working capital (raw materials, operating expenses, marketing). - Context: The IPO forms part of a broader wave of new listings on BEI, with 22 new companies listed by mid-July 2025.
/data/photo/2022/04/26/62677b6a090df.jpg)
Summary: - Company and IPO: PT Niramas Utama, known for Inaco jelly and other desserts, intends an IPO under ticker JELI. Bookbuilding runs 15–22 June 2026; final price to be determined after bookbuilding. - Offering size and target funding: Up to 350 million new shares (about 25.93% of issued and paid-up capital post-IPO) with an indicative price range of Rp 900–Rp 1,120 per share. Estimated fundraising: Rp 315 billion to Rp 392 billion, depending on final price. - Use of proceeds: Primarily for capital expenditure and expansion, including: - ~51.04% for equity investment in subsidiary Niramas Pandaan Sejahtera to boost gummy candy and jelly production capacity. - ~18.36% for purchasing machinery and equipment to improve storage, logistics, and capacity. - ~10.63% for paying down short-term debt (to reduce debt from Rp 94 billion to ~Rp 54 billion at Bank Mandiri). - ~19.97% for working capital. - Financial snapshot (as of 31 Dec 2025, per prospectus): Revenue Rp 753 billion; net profit Rp 39.02 billion; EBITDA margin around 13.58%; ROE 26.82%; ROA 7.07%. - Timeline post-bookbuilding: Final price determined after 22 June 2026; OJK approval target 29 June 2026; Offering dates 1–3 July 2026; expected listing on BEI on 7 July 2026. Underwriter: PT Sucor Sekuritas. - Market context: Brand is relatively well-known in Indonesia; focus on capacity expansion and logistics to support growth. Investors should assess valuation, growth prospects, ownership structure, and business risks before investing.
/2017/03/06/2034016999p.jpg)
Ringkasan relevan (JECX IPO): - Perusahaan: Nitrasanata Dharma, pengelola jaringan JEC Eye Hospitals & Clinics. Saham akan diperdagangkan di Bursa Efek Indonesia dengan skema IPO. - Kode saham: JECX. Target menawarkan sekitar 487,98 juta saham baru (≈ 10% dari modal ditempatkan dan disetor pasca IPO) dan 162,88 saham divestasi dari pemegang tetap (2% dari modal ditempatkan disetor pasca IPO) milik Dr. Waldenius Girsang. - Kisaran harga IPO: Rp1.200–Rp1.400 per saham. - Potensi dana yang diraup: sekitar Rp683,17 miliar (≈ Rp455,45 miliar dari saham baru, ≈ Rp227,72 miliar dari saham divestasi). - Program alokasi saham karyawan: sekitar 2,29% dari jumlah saham yang ditawarkan (≈ 11,16 juta saham). - Penggunaan dana IPO: - Pembayaran pokok pinjaman lebih awal kepada Bank Central Asia (BBCA): Rp49 miliar - Pembayaran pokok pinjaman lebih awal kepada HSBC Indonesia: Rp100 miliar - Pinjaman/pendanaan ke perusahaan anak: Rp185 miliar (Rp50 miliar ke PT Nitra Sanata Bali, Rp100 miliar ke PT Orbita, Rp35 miliar ke PT JEC Candi Sejahtera) - Modal kerja dan biaya operasional operasional harian hingga 31 Desember 2027 (sisa dana) - Tujuan penggunaan sisa dana: modal kerja dan biaya operasional yang terkait dengan kegiatan operasional sehari-hari, dialokasikan secara bertahap hingga 31 Desember 2027.
Summary: - Company and IPO: PT Nitrasanata Dharma (operator of the Jakarta Eye Center, JEC) aims to raise up to 683.2 billion rupiah ($38.3 million) via an IPO, listing on the Indonesia Stock Exchange as JECX on July 7 after a bookbuilding period June 22-24. - Offering details: Up to 487.98 million shares offered at 1,200-1,400 rupiah each; includes both newly issued shares and secondary shares from an existing shareholder (total deal size at the top end: 683.2 billion rupiah). Sole lead underwriter: Trimegah Sekuritas Indonesia. - Use of proceeds: Part to reduce debt and strengthen the balance sheet (about 140 billion rupiah to partially repay loans from BCA and HSBC Indonesia), around 185 billion rupiah to subsidiaries (including Bali and other regional units), with the remainder for working capital and operational needs. - Healthcare IPO context: Part of a rare wave of healthcare IPOs on the Indonesia Stock Exchange, following Esa Medika Mandiri and Prodia Diagnostic Line, all aiming to list in early July. - Business profile: One of Indonesia’s largest eyecare networks, operating five specialist eye hospitals and 11 clinics across major cities (Jakarta, Semarang, Surabaya, Makassar, Denpasar, Purwokerto, Bekasi, Kendari). Flagship JEC@Menteng serviced ~73,000 patients and generated 214.8 billion rupiah revenue in 2025. - Financials (2023-2025): Revenue rose to 977.4 billion rupiah in 2025 (from 887.7 billion in 2024 and 825.1 billion in 2023). Net profit attributable to shareholders: 73.8 billion rupiah in 2025 (vs. 65 billion in 2024). - Growth and expansion: Expanding into Bali via JEC Bali@Sanur in a new Sanur Health Special Economic Zone, targeting medical tourism; slated to begin operations in 2027 with expected ~30,000 patient visits in its first year. - Notable stake: OMNI Hospitals (PT Sarana Meditama Metropolitan Tbk) holds about 28% pre-IPO stake in Nitrasanata Dharma.
Summary: - The page outlines a proposed initial public offering (IPO) for PT Niramas (and its subsidiary-related use of funds). Key offering details: - Maximum shares offered: 350,000,000 new ordinary shares - Nominal value per share: Rp100 - Offer price range: Rp900 to Rp1,120 per share - Maximum total new capital (emisi): Rp392,000,000,000 - Use of proceeds from the IPO (level I allocations and other uses): - ~51.04%: Capital injections into subsidiary PT NPS as equity, to fund production capacity expansion (machines, equipment) for gummy candy and jelly products to meet domestic and export demand. - ~18.36%: Working capital-focused capex to purchase production machinery, equipment, and improve storage/logistics capacity. - ~10.63%: Partial repayment of short-term loans (KMK 1 and KMK 2) to Bank Mandiri; post-payment remaining loan balance around Rp54,000,000,000. - ~19.97%: General corporate purposes and other working capital needs. - Financial highlights (selected figures; likely from a recent period): - Equity: Rp145,520,145,316 (current) vs Rp118.5b (prior) vs Rp753,050,908,792 and Rp788,428,762,579 and Rp838,941,159,796 (context not fully clear without table headers). - Revenue and gross profit: Revenue around Rp462.3b (previous period) and Rp528.8b (prior period) and Rp592.68b (likely forecast/next period); gross profit around Rp290.78b (latest) vs Rp259.61b and Rp? (partial data). - Net income (laba bersih): Laba sebelum pajak sekitar Rp51.70b; laba berjalan sekitar Rp39.03b; last year/net income figures show significant growth/decline depending on period. - Earnings per share (basic/diluted): Rp39.02 (latest) vs Rp12.92 and Rp2.40 (prior periods). - Profitability and leverage metrics (selected): - ROE: ~26.82% (latest) vs ~9.81% and ~1.57% (prior) - ROA: ~7.07% vs ~2.23% and ~0.33% (prior) - Current ratio: ~1.14 - Debt-to-assets: ~0.74 - Debt-to-equity: ~2.79 - Interest Coverage Ratio: ~4.30 - DSCR: ~2.15 - EBITDA margin and growth: EBITDA/Revenue around 13.58% - Overall impression: - The document presents an IPO plan with detailed use-of-proceeds, targeted investments to expand production capacity and logistics, and mixed but improving profitability and leverage indicators
Summary: - JELI shows improving profitability despite declining revenue ahead of its IPO. - Revenue: FY23–FY25 declines from Rp 838.9b to Rp 753.1b. - Net profit: rises from Rp 2.4b (FY23) to Rp 39.0b (FY25). - Gross profit rises from Rp 246.5b to Rp 290.8b in the same period. - Net profit margin improves from 0.2% (FY23) to 5.2% (FY25); gross margin from 29.4% to 38.6%; operating margin from 0.8% to 6.9%. - Key driver: disciplined efficiency and portfolio optimization. - Management reduced low-margin, low-contribution products. - Focus on higher-margin revenue through price optimization, cost of goods, and production procurement efficiency. - Market position and brand strength: - INACO under JELI dominates the national dessert segment. - Jelly category: ~49.57% national market share; Nata de Coco 19.87%; Pudding 16.01%. - Domestic market accounts for >95% of revenue, signaling strong local demand but exposure to domestic volume trends. - Business mix and growth indicators: - Gross profit growth outpaced revenue decline, indicating improved product mix. - Export revenue shows a recovery in FY25 (Rp 15.73b from Rp 14.70b in FY24) after a prior dip. - IPO use of proceeds (allocation): - 51.04% for expanding production capacity at PT NPS. - 19.97% for working capital. - 18.36% for capital expenditures. - Investment implications for JELI IPO: - Positive signals from stronger margins and profitability trajectory. - Large portion of funds earmarked for capacity expansion suggests anticipated demand growth and potential upside if margins sustain. - Predominantly domestic exposure may matter for growth drivers and sensitivity to local market conditions. If you want, I can condense further into a one-sentence takeaway or extract the exact margin trends in a compact bullet list.
Summary: - Company: PT Nitrasanata Dharma, operator of the Jakarta Eye Center (JEC) eyecare network. - IPO size: Up to 683.2 billion rupiah (~$38.3 million) via an initial public offering. - Share details: 487.98 million shares offered at 1,200–1,400 rupiah each; includes both new and secondary shares. - Listing: Planned on the Indonesia Stock Exchange under ticker JECX, with bookbuilding June 22–24; listing date July 7. - Underwriter: Sole lead underwriter is Trimegah Sekuritas Indonesia. - Use of proceeds: Part to reduce debt (about 140 billion rupiah to repay loans from Bank Central Asia and HSBC Indonesia); about 185 billion rupiah to subsidiaries (including Bali and regional units); remaining for working capital and operations. - Market context: Part of a wave of Indonesian healthcare IPOs in 2024–2025; other recent entrants include Esa Medika Mandiri and Prodia Diagnostic Line. - Business profile: One of Indonesia’s largest eyecare networks with five specialist eye hospitals and 11 clinics across major cities (Jakarta, Semarang, Surabaya, Makassar, Denpasar, Purwokerto, Bekasi, Kendari). JEC@Menteng (flagship) served ~73,000 patients and generated 214.8 billion rupiah in revenue in 2025. - Financial highlights (2023–2025): Revenue rose to 977.4 billion rupiah in 2025 (from 887.7 billion in 2024 and 825.1 billion in 2023). Net profit attributable to shareholders increased to 73.8 billion rupiah in 2025 (vs. 65 billion in 2024). - Growth/expansion: Planning JEC Bali@Sanur in Sanur Health SEZ, targeting medical tourism; expected to begin operations in 2027 with ~30,000 patient visits in its first year. - Notable shareholder: PT Sarana Meditama Metropolitan Tbk (OMNI Hospitals) holds about 28% ahead of the IPO.
- Perusahaan: PT Nitrasanata Dharma Tbk (JECX), pengelola Jakarta Eye Center, anak usaha EMC Healthcare milik Grup Emtek via SAME. - IPO: JECX siap melakukan penawaran umum perdana (IPO) di Bursa Efek Indonesia. - Jumlah saham: 487,98 juta lembar; setara sekitar 15% modal ditempatkan dan disetor pasca-IPO. - Jenis saham: 325,32 juta lembar (10%) saham baru dari portepel perseroan; 162,66 juta lembar saham divestasi milik Dr. Waldensius Girsang. - Rentang harga IPO: Rp1.200–Rp1.400 per lembar. - Dana yang diraup diproyeksikan maksimum sekitar Rp683,18 miliar. - Alokasi penggunaan IPO: - 52,41% untuk modal kerja operasional. - Sisa untuk pelunasan utang. - Rinciannya meliputi pembayar pinjaman awal ke BBCA ( Rp40 miliar) dan HSBC Indonesia ( Rp100 miliar); modal kerja NSB ( Rp50 miliar); pembayaran utang anak usaha Orbita ( Rp100 miliar) dan JEC Candi Sejahtera ( Rp35 miliar). - Struktur pemegang saham utama sebelum IPO (top 6): SAME 28%, Dr. Darwan Madja Purba 13,11%, PT Magna Selaras Lestari 10,15%, Rayyan Farrel Wardhana Istiantoro 9,89%, Nabbil Wardhana Istiantoro 9,89%, Dr. Waldensius Girsang 6,22%. - Pemegang saham lain: lebih dari 60 dokter spesialis di jaringan JEC memiliki kepemilikan bervariasi namun masing-masing di bawah 5%. - Jadwal: bookbuilding hingga 24 Juni 2026; proyeksi penawaran umum 1–3 Juli 2026; pencatatan perdana (listing) 7 Juli 2026. - Context: IPO JECX mengikuti tren IPO perusahaan layanan kesehatan Indonesia.
Summary: - Company: PRDL (Diagnostic/clinical chemistry, hematology, instrument segments) - 2025 performance highlights: - Revenue: Rp 74.4 bn (+26.8% YoY from Rp 58.7 bn in 2024) - Gross profit: Rp 45.4 bn (+31.3% YoY) - Net profit: Rp 17.0 bn (+69.9% YoY) - Key drivers: distribution network expanded from 21 to 45 distributors; stronger sales volumes; new products in clinical chemistry, hematology, and instruments; recovery of previously reserved receivables - Segment contributions: - Clinical Chemistry: Rp 60.4 bn (81.2% of total; +19.4% YoY) - Hematology: Rp 4.1 bn (+284.6% YoY), fastest growth, returning to profitability - Instrument: Rp 8.8 bn (+28.1% YoY) - IPO proceeds allocation (approx. Rp 35.7 bn of total IPO funds): - Deleveraging: repay outstanding bank loans (BCA and Panin Bank) to reduce leverage and interest costs - Capex: ~28.9% for production/calibration equipment, software, facility upgrades, lab enhancements, and vehicles (capacity expansion) - Working capital: ~8.5% for raw materials - Valuation and earnings upside: - Implied market cap: Rp 174.3–209.1 bn - 2025 P/E: 10.2x–12.3x - Peers comparison: PRDA (11.1x), IRRA (8.8x), OMED (13.9x) – PRDL sits near industry average - Debt repayment from IPO proceeds could cut annual financing costs by ~Rp 1.0–1.2 bn, supporting future earnings growth Key takeaway: PRDL shows solid 2025 growth driven by broader distribution and product mix, with IPO funds slated to de-leverage and capex for capacity, potentially boosting profitability and future earnings.
Summary: - PRDL (PT Prodia Diagnostic Line Tbk) is an Indonesian health sector company producing and assembling in vitro diagnostics (IVD) equipment and reagents, serving hospitals, clinical labs, government health facilities, private clinics, and research institutions. It also engages in distributing lab equipment, calibration, testing/inspection, and maintenance services. - IPO details: Plans to offer 522.9 million new shares (about 30% of issued and paid-up capital post-IPO) with a target fundraise of Rp62.74 billion. Book-building period: 18–23 June 2026. Indicative offer price: Rp100–Rp120 per share. - Product and service categories (4 main groups): 1) Reagents/instruments for health parameters (liver, kidney, cholesterol, glucose, etc.) 2) Reagents/instruments for complete blood count (red/white blood cells, platelets) 3) Diagnostics for infectious diseases, immune disorders, molecular-based tests 4) Laboratory analyzers, diagnostic instruments, incubators, and related lab support equipment - Commercial scope: Own brands, distributor brands, and principal brands; about 1,083 active SKUs sold to Indonesian health facilities; distribution across 370 of 514 districts/cities in 38 provinces; serving ~7,611 end users (government and private sectors). - Growth and financial highlights (2025 vs 2024): - Revenue: Rp74.37 billion (2025) up 26.8% from Rp58.66 billion. - Gross profit: Rp45.35 billion, up 31.3% from Rp34.54 billion. - Operating profit: Rp24.36 billion, up 60% from Rp15.23 billion. - Net profit: Rp16.99 billion, up 69.9% from Rp10.0 billion. - EPS: Rp13.93 per share (vs Rp8.19 prior year). - Balance sheet (end-2025 vs end-2024): - Total assets: Rp194.43 billion, up 5.6% from Rp184.08 billion. - Fixed assets increasing to Rp135.01 billion (from Rp107.07 billion), signaling capacity expansion. - Total liabilities: Rp111.37 billion, down from Rp117.90 billion. - Equity: Rp83.06 billion, up 25.5% from Rp66.18 billion. - Strategic implications: Solid 2025 growth, improving profitability and stronger equity base, with ongoing capacity expansion ahead of/around the IPO. The company aims to leverage distribution reach and a broad product portfolio to support long-term demand in healthcare diagnostics.
Summary: - Esa Medika Mandiri Tbk (EMMI) plans an IPO on the Indonesia Stock Exchange, effective July 8, 2026. - Bookbuilding: June 22–24, 2026; public offering period: July 2–6, 2026; allocation/date of share distribution: July 6–7, 2026. - Offering: up to 522.85 million new shares; price range: Rp446–Rp515 per share; target fresh funds: Rp269.27 billion. - Use of proceeds (from IPO): Rp50 billion to partially repay debt; ~11.8% for capex (construction of a factory in Cikupa); up to ~68.7% for working capital (procurement of goods, raw materials, inventories). - If IPO funds are insufficient, company may use internal cash or external financing from banks/other institutions. - Underwriters: PT BRI Danareksa Sekuritas and PT INA Sekuritas Indonesia (full commitment). - Company financials (as of 31 Dec 2025): total assets Rp564.44 billion; liabilities Rp419.42 billion; equity Rp145.01 billion. - 2025 sales: Rp454.64 billion; cost of goods sold Rp291.21 billion; gross profit Rp163.21 billion; net profit rose from Rp0.94 billion (2023) to Rp11.01 billion (2024) to Rp34.13 billion (2025).
Summary: - Company: PT Esa Medika Mandiri Tbk (EMMI) approaching IPO on BEI. - 2025 results: Net profit rose 188.23% to Rp32.44 billion (from Rp11.25 billion in 2024). - Revenue: Net sales grew 18.11% to Rp454.64 billion (from Rp384.93 billion in 2024). - Profit drivers: Government segment dominates revenue with Rp436.89 billion (98.49% of total); non-government segment contributed Rp17.74 billion. Growth driven by success in multiple tenders, including IsDB and World Bank. - Gross profit: Rp163.43 billion, up 20.24% from Rp135.91 billion in 2024. - Costs: Cost of goods sold rose to Rp291.21 billion from Rp249.02 billion. Operating expenses: Rp96.59 billion (slightly up from Rp95.32 billion). Interest expense: Rp30.44 billion (up from Rp29.51 billion). - Balance sheet: Total assets Rp564.44 billion as of Dec 2025, down 20.99% from Rp714.39 billion in 2024 due to early debt repayments. Equity rose 97.64% to Rp145.01 billion; liabilities reduced 34.57% to Rp419.42 billion. - Financial ratios: ROA 6%, ROE 22%. - IPO details: Plans to offer up to 522.85 million new shares (about 30% of issued and paid-up capital). Indicative price range: Rp446–Rp515 per share. Targeted fundraising: up to Rp269.27 billion. - IPO timeline: Pre-IPO offer period June 22–24, 2026; expected listing on BEI on July 8, 2026. - Outlook: Management optimistic about continued growth in the health sector.
Summary: - BR I Danareksa Sekuritas (BRI Danareksa) says its IPO mandate remains on track despite BEI’s planned update to free float rules. - BEI plans a minimum free float of 15% for new listed companies, with potential minimums up to 25% depending on market capitalization (per BEI draft Regulation I-A revisions). - BEI draft specifics: - Less than Rp5 trillion market cap: minimum free float 25%. - Rp5–Rp50 trillion: minimum free float 20%. - Rp50 trillion and above: minimum free float 15%. - BRIDS targets 5–6 IPOs in 2026 across sectors (medical, construction, property, shipping, energy) and will adjust IPO structures once BEI finalizes the new rules. - Current status: no discussions to delay any planned transactions; preparations for H1 2026 completions continue as scheduled; valuation discussions with each potential issuer ongoing. - BRIDS intends to align once BEI officially issues the new free float regulation, maintaining flexibility to respond to policy changes.
Esa Medika Mandiri Tbk (EMMI) akan melakukan IPO untuk menjual hingga 522,86 juta saham baru, setara dengan 30% modal ditempatkan dan disetor penuh, dengan harga penawaran Rp446–Rp515 per lembar. Potensi dana yang terkumpul maksimal sekitar Rp269,27 miliar setelah biaya emisi. IPO juga menyediakan maksimal 52,29 juta saham (10%) untuk program Employee Stock Allocation (ESA). Dana dari IPO akan digunakan untuk memperkuat struktur permodalan dan ekspansi, termasuk sekitar Rp50 miliar untuk sebagian pokok utang, sekitar 11,8% untuk belanja modal pembangunan pabrik di Cikupa, dan sekitar 68,7% untuk kebutuhan modal kerja. Rencana dividen tunai mulai buku tahun 2027 dengan rasio hingga 30% dari laba bersih, namun realisasi dividen tergantung laba, arus kas, dan kebutuhan modal. Performa 2025: penjualan bersih naik 18,11% yoy menjadi Rp454,64 miliar; laba bersih naik 209,99% yoy menjadi Rp34,13 miliar. Long-term debt to equity ratio (liabilitas jangka panjang terhadap ekuitas) turun menjadi 0,74x pada 2025 (dari 1,28x di 2023). Penawaran awal 22–24 Juni 2026; pendaftaran umum 2–6 Juli 2026; pencatatan di BEI 8 Juli 2026. Underwriter: BRI Danareksa Sekuritas dan INA Sekuritas Indonesia.
- Company and IPO: PT Nitrasanata Dharma, operator of the Jakarta Eye Center (JEC) eyecare network, plans an IPO to raise up to 683.2 billion Indonesian rupiah (~$38.3 million), through a mix of new and secondary shares. Ticker: JECX, listing on July 7 after a bookbuilding period June 22–24. Sole lead underwriter: Trimegah Sekuritas Indonesia. - Offering details: Up to 487.98 million shares offered at 1,200–1,400 rupiah each. IPO includes both newly issued shares and secondary shares from an existing shareholder. - Use of proceeds: Part to reduce debt (about 140 billion rupiah, including loans from Bank BCA and HSBC Indonesia), about 185 billion rupiah to subsidiaries (e.g., Bali and other regional units), with remaining funds for working capital and operations. - Financials (latest available): 2025 revenue of 977.4 billion rupiah (≈$54.8 million), up from 2024 revenue of 887.7 billion rupiah and 2023 revenue of 825.1 billion rupiah. Net profit attributable to shareholders: 73.8 billion rupiah in 2025 (up from 65.0 billion in 2024). - Operations and scale: Operates five specialist eye hospitals and 11 clinics across major Indonesian cities (Jakarta, Semarang, Surabaya, Makassar, Denpasar, Purwokerto, Bekasi, Kendari). Flagship JEC@Menteng hospital served ~73,000 patients and generated ~214.8 billion rupiah in revenue in 2025. - Growth initiatives: Expanding beyond traditional markets with JEC Bali@Sanur in the Sanur Health Special Economic Zone, targeting medical tourism; expected to begin operations in 2027 and anticipate about 30,000 patient visits in its first year. - Notable shareholders: PT Sarana Meditama Metropolitan Tbk (OMNI Hospitals) holds a 28% stake ahead of the IPO.
Summary: - IPO: PT Chandra Daya Investasi Tbk (CDIA) on Indonesia Stock Exchange sets a new record. - Offering period: Oversubscription rate of 563 times in the pooling allotment, with total orders around Rp 33.6 trillion. - Overall oversubscription: 15.06x across the entire offering, with total orders Rp 35.7 trillion (including fixed and pooling allotments). - Investor demand: About 400,162 SIDs and 431,482 Sub Rekening Efek participated. - Debut performance: CDIA shares rose 35% to Rp 135 per share; demand surged with an order queue totaling about 125 million lots (approx Rp 3.2 trillion), a new IPO queue record in the regular market. - Underwriters: Lead underwriter Henan Sekuritas, plus DBS Vickers Sekuritas, Trimegah Sekuritas, BNI Sekuritas, BCA Sekuritas, and OCBC Sekuritas. - Management view: Fransiskus Ruly Aryawan, CDIA President Director, describes the listing as a strategic milestone for CDI Group, aiming to support infrastructural growth and connectivity in Indonesia and Southeast Asia.
Summary: - The Annual General Meeting of Shareholders (RUPS Tahunan) was attended by shareholders representing 532,654,200 shares (70.46% of total issued voting shares). - Key resolutions approved: 1) Approved the Company’s Annual Report for 2024, including the Activities Report, the Supervisory Report by the Board of Commissioners, and ratified the Consolidated Financial Statements for the year ended 31 December 2024. 2) Granted full acquittal (acquit et de charge) to all members of the Board of Directors and the Board of Commissioners for their management and supervision in 2024. 3) Approved appropriation of net profit for the year ended 31 December 2024 (IDR 76,583,066,000) as: - IDR 7,560,000,000 to cash dividends - IDR 2,900,000,000 for Tantiem (bonuses) for Directors & Commissioners - IDR 5,000,000,000 to the Reserve Fund - IDR 61,123,066,000 to Retained Earnings 4) Resolved to appoint the Company’s Public Accountants/Auditing Firm for 2025, including terms and honorarium, and to appoint or replace if necessary. 5) Approved the honorable discharge of Mr. Ignatius Nugraha Widiyanta (Nugraha Widiyanta) from his position as Director and to appoint new Board members for the term 11 June 2025 to 11 June 2028, with the following lineup: - President Director: Mrs. Mary Ang Santoso - Directors: Antonius Benady, Jimmy Wijaya Joeng-Pramusinto Bambang Pramudiono (Pramusinto) - President Commissioner: Santoso - Commissioners: Tommy Wijaya - Independent Commissioner: Drs. Agus Kristiyono, AKT, MBA - Term of new Board members set to commence 11 June 2025 until 11 June 2028.
Summary: - Company: PT Nitrasanata Dharma, operator of the Jakarta Eye Center (JEC) network, plans an IPO to raise up to 683.2 billion rupiah (~$38.3 million). - Offering: 487.98 million shares at 1,200–1,400 rupiah each; includes both new and secondary shares. Listing ticker: JECX. - Timeline: Bookbuilding June 22–24; listing expected July 7, 2026. - Underwriter: PT Trimegah Sekuritas Indonesia (sole lead underwriter). - Use of proceeds: Part to reduce debt (about 140 billion rupiah to Banks BCA and HSBC Indonesia), ~185 billion rupiah to subsidiaries (e.g., Bali and regional units), remaining for working capital and operations. - Market context: One of several healthcare IPOs on the Indonesia Stock Exchange in a healthcare sector IPO surge. - Business profile: One of Indonesia’s largest eyecare networks, founded 1984 as Klinik Mata Jakarta; rebranded to JEC in 1993; introduced LASIK in 1997; first eye hospital in Indonesia in the World Association of Eye Hospitals (2010). - Ownership: Major shareholder OMNI Hospitals (PT Sarana Meditama Metropolitan Tbk) holds about 28% ahead of the IPO. - Operations and scale: Five specialist eye hospitals and 11 clinics across Jakarta, Semarang, Surabaya, Makassar, Denpasar, Purwokerto, Bekasi, Kendari. Flagship JEC@Menteng posted 214.8 billion rupiah revenue in 2025 from ~73,000 patients at that site. - Financials (recent): Revenue 2025: 977.4 billion rupiah; 2024: 887.7 billion; 2023: 825.1 billion. Net profit attributable to shareholders 2025: 73.8 billion rupiah; 2024: 65 billion. Key takeaway: JEC seeks to fund debt reduction and regional expansion (including Bali and medical tourism-focused Bali@Sanur), leveraging a growing Indonesian healthcare services market with a newly listed eye-care network operator.
Summary: - IPO status: Superbank Indonesia’s IPO was massively oversubscribed at 318.69 times, with more than 1 million investor orders ahead of its Jakarta listing on Dec. 17. - Market impact: The strong demand signals market confidence in Superbank’s fundamentals and growth, and it may bolster liquidity and curb risk for the SUPA ticker post-listing. - Business shift and growth: Since 2022, Superbank pivoted to a digital-focused model. By 2024, digital customers exceeded 2.7 million; deposits rose to Rp 4.94 trillion (436% YoY); loans disbursed reached Rp 6.43 trillion (120% YoY); gross NPL 2.27% and net NPL 0.35%. - 2025 momentum: As of Oct 2025, profit before tax was Rp 102 billion; net interest income rose 173% YoY to Rp 1.3 trillion; digital-app customer base surpassed 5 million (launched June 2024). DPK grew 168% YoY to Rp 10.6 trillion; loan disbursement Rp 9.1 trillion (up 70% YoY); total assets up 72% YoY to Rp 17.6 trillion. - Financial position (2024 results): Total assets Rp 11.39 trillion; liabilities Rp 6.15 trillion; equity Rp 5.25 trillion. - Notable partnerships/ownership: Backed by Grab, Emtek, Singtel, GXS, and KakaoBank, enhancing ecosystem synergies (e.g., OVO, Grab integrations). - Related note: Additional article indicates Superbank booked Rp 122.4 billion pre-tax profit through November 2025, reflecting scaling profitability from growth in loans, deposits, and assets.
- Sucor Sekuritas CEO Bernadus Wijaya states that three jumbo companies, each with market cap over IDR 1 trillion, are in the IPO pipeline for 2026. - One of the three is expected to list in H1 2026; the other two in H2 2026. Details on the issuers are not disclosed due to confidentiality. - Sucor Sekuritas is underwriting SUPA’s IPO alongside Mandiri Sekuritas, CLSA Sekuritas Indonesia, and Trimegah Sekuritas. - SUPA’s IPO was highly oversubscribed (over 300x) with more than 1,000,000 orders; the listing aligns with Emtek Group’s broader digital banking strategy and ecosystem, including Grab collaboration and various business units (media, education, hospitals). - RATU (Raharja Energi Cepu Tbk) is another issuer Sucor Sekuritas underwrote; RATU’s IPO raised IDR 624.46 billion, with initial price IDR 1,150 and a peak rally of ~795.65% from IPO (as of the latest noted date). - RATU’s stock subsequently surged, hitting ARA limits for multiple sessions post-IPO.
Summary: - Fokus: Saham consumer staples tetap menarik meski ada tekanan nilai tukar dan daya beli. Rekomendasi konsensus BRIDanareksa (25/5/2026) menilai INDF sebagai pilihan paling menarik dari sisi valuasi dan pertumbuhan laba, sementara ICBP masih dibayangi pelemahan kurs. - INDF (Indofood Sukses Makmur): - Valuasi paling murah di antara peers, berpotensi re-rating seiring berkurangnya holding discount. - Q1-2026 penjualan Rp33,9 triliun (+7,4% YoY); laba bersih Rp2,95 triliun (+8,6% YoY). - Model bisnis terdiversifikasi: food (melalui ICBP) dan agribisnis. - Valuasi: PE sekitar 5x; PBV sekitar 0,76x. - Dinilai menawarkan kombinasi value dan growth yang seimbang. - ICBP (Indofood CBP Sukses Makmur): - Penjualan Q1-2026 sebesar Rp21,7 triliun (+7,6% YoY); laba bersih turun sekitar 3% YoY menjadi Rp2,57 triliun. - Penurunan laba didorong rugi selisih kurs (FX) akibat pelemahan rupiah, bukan masalah inti bisnis. - Margin operasional kuat: operating margin sekitar 21,3%. - Valuasi: PE ~7,8x; PBV ~1,48x. Direkomendasikan akumulasi bertahap ketika stabilitas rupiah membaik. - MYOR (Mayora Indah): - Laba bersih melonjak 37% YoY jadi Rp946 miliar; penjualan turun 4,7% YoY menjadi Rp9,4 triliun. - Efisiensi biaya dan margin kotor membaik (GPM 26,6% dari 21,9%). - Meski momentum laba kuat, valuasi berada di premium (PE ~11x; PBV ~2,21x). - Perlu dicermati pemulihan volume penjualan domestik; meski net cash, masuk lebih lanjut disarankan hanya jika volume terkonfirmasi rebound. - Makro dan risiko: - Inflasi April 2026 menurun ke 2,42% mendukung daya beli. - Risiko utama: BI rate naik 50 bps menjadi 5,25% (Mei 2026) dan pelemahan rupiah ke sekitar Rp17.700/USD, berpotensi memukul sektor consumer staples. - Kesimpulan praktis: - INDF adalah saham with value-leaning appeal dan growth yang seimbang, harga murah relatif terhadap ekspektasi pertumbuhan. - ICBP layak akumulasi bertahap jika rupiah stabil; laba terdampak FX
Summary: - Topic: ICBP (Indofood CBP Sukses Makmur Tbk) as a defensif stock with growth prospects. - Position: Strong defensives in Consumer Non-Cyclicals with stable daily consumption demand (dairy, snacks, seasonings, instant noodles). - Core strengths: Dominant brand (Indomie), wide distribution, product diversification, and international exposure (Pinehill acquisition expanding in Africa, Middle East, and South Asia). - Revenue profile: Resilient earnings across economic cycles due to staples-like demand; main driver remains instant noodles. - Market valuation: 2026E P/E around 9.3x, cheaper than peers (MYOR ~18.5x, ULTJ ~14.8x, KLBF ~21.0x). Sum-of-the-Parts suggests intrinsic value above current price; ICBP seen as undervalued relative to business quality. - Segmentation: Instant noodles is the core driver; dairy, beverages, snacks, and nutrition provide diversification and stability. - Risks: - Raw material/import dependency (wheat, global commodities). - FX exposure (IDR vs USD) impacting production costs. - Shifts in consumer preference toward healthier options requiring ongoing innovation. - International expansion increases governance and cross-border oversight complexity. Key takeaway: ICBP is portrayed as a robust, defensively positioned consumer goods company with solid brand equity and international growth, currently trading at a relatively low valuation (around 9.3x 2026E P/E) versus peers, though it faces commodity, currency, and innovation/macro risks.
Summary: - Context: With the Indonesia Stock Exchange index (IHSG) weakening to 5,941 on June 3, 2026, investors are favoring defensive healthcare stocks, particularly hospital operators, due to inelastic demand for health services. - Key hospital emitents on BEI: MIKA (Mitra Keluarga), SILO (Siloam), HEAL (Hermina), SRAJ (Mayapada). KLBF (farmasi) also mentioned for contrast. - Q1 2026 financial highlights: - MIKA: Revenue Rp1.36 trillion (+6.6% YoY); Net income Rp325.8 billion. Noted as highly efficient with strong cash position; EBITDA margin 37.97%. - SILO: Revenue Rp3.28 trillion (+7.9% YoY); Net income Rp293.6 billion (+14.8% YoY); Gross margin ~38.15%, Net margin ~8.96%; DER 0.50x. - HEAL: Revenue Rp1.78 trillion (+5.4% YoY); estimated net income around Rp110 billion (approximate); margin pressured by expansion costs. - SRAJ: Revenue ~Rp825 billion (+7.8% YoY); net income still negative (loss per share ~ Rp7.40, vs Rp2.33 prior year); on a recovery path but weak profitability; ROE highly negative (-20.95%), net margin negative (-9.87%), utilization/balance sheet fragile; potential high upside if recovery and asset utilization improve. - KLBF (comparison): Revenue Rp9.68 trillion (+10.1% YoY); net income down ~4.4% due to depreciation from rupiah weakness affecting raw material costs; gross margin high but pressured. - Profitability and risk notes: - MIKA and SILO showing positive earnings growth driven by private-patient mix and operating efficiency. - HEAL expanding aggressively; short-term margin pressures but mid-term prospects favorable if expansion yields scale. - SRAJ in recovery phase with high risk but potential large upside if stabilization and asset utilization improve. - KLBF shows solid revenue growth but impacted by currency and cost pressures. - Valuation signals (consensus targets): - MIKA: 12-month target around Rp2,949 (high Rp3,600, low Rp2,200); TradingView target ~Rp3,111. - SILO: 12-month target range Rp2,850–Rp3,220; current price around Rp2,390; PER ~27.7x (premium justified by scale). - HEAL: Target range Rp1,450–Rp1,950 depending on broker. - SRAJ: Some targets as high as Rp17,000 reflecting optimistic recovery expectations, but with notable risk. - Strategic takeaways for investors: - MIKA and SILO emerge as the more defensible, profit-generating hospital operators with healthier margins and balance sheets
Summary: - 2026 outlook: Indonesian hospital stocks remain attractive as demand for health services rises and hospital networks continue to expand. Sector viewed as defensively resilient but stock performance will vary by issuer. - Key growth drivers: - Higher patient volumes from both BPJS and private payers. - Expansion of hospital networks boosting bed occupancy rate (BOR). - Potential catalysts: Standard Inpatient Care Class (KRIS) for BPJS and strengthened Center Of Excellence services to improve domestic utilization and deter medical tourism. - Notable analysts’ views: - Muhammad Wafi (KISI): Upbeat on patient volume growth; KRIS and Center Of Excellence as catalysts. Cites risk from high depreciation/interest due to expansions. - David Kurniawan (IPOT): Volume growth supports revenue, but impact on margins and stock moves uneven; BPJS tariff pressure could constrain margins; rising operating costs and new hospital utilization risk in near term. - Alif Ihsanario (Ciptadana Sekuritas): Risks include doctor supply constraints and higher medical cost inflation; potential slower recovery of patients who previously sought care abroad; competition from government hospital networks; macro risk from weak economy affecting elective high-cost services. - Additional context: 2025 performance showed mixed results; MIKA and SILO posted net profit growth, while HEAL and SRAJ have upside if margins and asset utilization improve. - Stock views and targets (buy/add recommendations): - KISI: Buy on MIKA ( Rp 3,100 target ), SILO ( Rp 3,000 ), HEAL ( Rp 1,450 ), SRAJ ( Rp 17,000 ). - IPOT: Buy on MIKA ( Rp 2,800 ). - Mirae Asset Sekuritas (Nafan Aji Gusta): Add on SILO ( Rp 3,170 ). - Risks to watch: - High depreciation and interest costs from expansions. - Shortage of medical specialists; volatile BPJS tariff margins. - Rising costs for medical equipment and drugs (including imports) due to currency and inflation. - Utilization risk for newly expanded hospitals; slower rebound in patients returning from overseas treatment. - Competition from government hospital networks; private insurer volatility; macroeconomic headwinds could delay demand for high-cost elective services.
Summary: - Indonesian health-sector stocks (OMED and PRDA) face risk from a weakening rupiah, which raises costs for imported raw materials and medical devices. - Rupiah depreciation in 2026 YTD: about Rp17,140 per USD (as of 18 Apr 2026), hitting multi-year weakness. - Import dependence: Hipelki data shows health-device imports up to about 45% of inputs early 2026, underscoring vulnerability to FX moves. - OMED (PT Jayamas Medica Industri Tbk): Significant import exposure; using natural hedging around 20% of cash, with suppliers secured for 4–6 months. May seek new suppliers to obtain better prices; price contracts in place help lock costs despite geopolitics. - PRDA (PT Prodia Widyahusada Tbk): Large import exposure but has FX hedges/ MOUs with suppliers; supply security expected to last through 6 months to year-end; FX impact currently deemed not significant. - Analyst view: FX pressure could raise cost of goods sold, potentially compressing margins in H1 2026, especially in the pharmaceutical subsector where ~90% of raw materials are imported. Hospitals may be more resilient due to pricing power. - Suggested stock picks and targets: MIKA (PT Mitra Keluarga Karyasehat Tbk) target Rp3,200; HEAL (PT Medikaloka Hermina Tbk) target Rp1,500, reflecting relative resilience vs. other health stocks. Key figures: - FX move: Rupiah down ~2.78% in 2026 year-to-date to ~Rp17,140/USD (as of 18 Apr 2026). - Import dependence: Up to ~45% of health-tools inputs imported (Hipelki data). - Short-term supply security: OMED and PRDA report 4–6 months of supply under current contracts; hedging and supplier MOUs mitigate near-term FX risk. Bottom line: - The health-emitter sector remains exposed to rupiah weakness mainly through imported inputs, with OMED and PRDA implementing hedging and supplier arrangements to mitigate impacts. Profitability risk is higher in pharma due to high import reliance; hospitals may fare better due to pricing power.
Summary: - Itama Ranoraya Tbk (IRRA) did not pay dividends for 2025, choosing to retain Rp65.53 billion for expansion and working capital. - Rp65.53 billion net income in 2025: Rp1.0 billion allocated to reserve, Rp64.53 billion to retained earnings as working capital to strengthen liquidity and fund strategic growth. - 2026 focus areas: - Increase sales capacity and expand distribution network nationwide. - Expand strategic partnerships with private sector, government, and new principals to broaden product portfolio. - Promote domestically produced medical devices (AKD) to support import substitution and tech development. - 2025 performance: - Net sales: Rp1.1 trillion, up 12.55% YoY. - Net profit: Rp65.53 billion, up 23.03% YoY (from Rp53.3 billion). - Net margin: 5.96%. - Total assets: Rp2.43 trillion. - Key segment: Diagnostic In Vitro contributed Rp693.48 billion; Medical Electromedik Steril Rp347.94 billion; Non-Electromedik Rp52.88 billion; other health products Rp5.91 billion. - Operational notes: - Laba ditahan used as working capital to support expansion and liquidity. - Expect positive demand in sterilization devices and disease-detection equipment into H1 2026. - Corporate move: headquarters relocation to ITS Tower, 21st floor, Jakarta Selatan, to improve efficiency.
Summary: - Platform: Electronic Indonesia Public Offering (e-IPO) portal for Indonesian IPOs and book-building. - Key features: Cek IPO, pesan (order), penjatahan (allocation), peluang investasi pasar perdana (primary market opportunities), and book building. - Active/current book-building window examples: - PT Prodia Diagnostic Line Tbk (PRDL) - Periode Book Building: 18 Jun 2026 – 23 Jun 2026 - Rentang Harga: Rp 100 – Rp 120 - Saham Ditawarkan: 5,229,000 Lot - PT Niramas Utama Tbk (JELI) Syariah - Periode Book Building: 15 Jun 2026 – 22 Jun 2026 - Rentang Harga: Rp 900 – Rp 1,120 - Saham Ditawarkan: 3,500,000 Lot - PT BSA Logistics Indonesia Tbk (WBSA) Syariah - Harga Final: Rp 168 - Tanggal Pencatatan: 10 Apr 2026 - Saham Ditawarkan: 18,000,000 Lot - PT Super Bank Indonesia Tbk (SUPA) - Harga Final: Rp 635 - Tanggal Pencatatan: 17 Dec 2025 - Saham Ditawarkan: 44,066,123 Lot - PT Abadi Lestari Indonesia Tbk (RLCO) - Harga Final: Rp 168 - Tanggal Pencatatan: 08 Dec 2025 - Saham Ditawarkan: 6,250,000 Lot - PT Pelayaran Jaya Hidup Baru Tbk (PJHB) Syariah - Harga Final: Rp 330 - Tanggal Pencatatan: 06 Nov 2025 - Saham Ditawarkan: 4,800,000 Lot - Other listed examples include EMAS, CHEK (Syariah), MERI (Syariah), BLOG (Syariah), CDIA, PMUI (Syariah), with respective price ranges and listing dates. - Scope: Provides a centralized view of active and upcoming IPOs with book-building periods, price ranges, number of shares/lot offered, sector classifications, and prospectus links. - Actionable for investors: Check current book-building windows, price ranges, and offered lots to gauge participation opportunities in upcoming Indonesian IPOs.
Summary: - Prodia Diagnostic Line (PRDL), an affiliate of Prodia Widyahusada, plans an IPO to raise up to Rp62.748 billion, selling up to 522.9 million shares (5,229 million lots) at a bookbuilding price between Rp100–Rp120 per share. Listing target on the Indonesia Stock Exchange (BEI) is July 9, 2026. - Use of proceeds: about 62.57% to repay principal facilities with banks (BBCA and PNBN) totaling Rp35.67 billion; 28.92% for capital expenditure (new machinery, calibration equipment, vehicles, software systems, production area relayout, and AHU Lab Biomolekuler); 8.51% for working capital (raw materials, R&D, marketing). - IPO process: Bookbuilding June 18–23, 2026; OJK effectiveness targeted June 29, 2026; public offering July 1–7, 2026; bookclose/allocation July 7, 2026; share distribution July 8, 2026; listing July 9, 2026. Sucor Sekuritas serves as administrator and underwriter. - Company profile: PRDL was founded as PT Dialine Systems Indonesia in 2010, renamed PT Prodia Diagnostic Line in 2011, operates in medical devices under KBLI 21015. It is an affiliated company under PT Prodia Utama, with current ownership: Prodia Utama ~51%, Prodia Widyahusada (PRDA) ~39%, DiaSys Diagnostic Systems GmbH ~10%. - Market/context: PRDL sees potential from government health initiatives, including a Free Health Check Program that covers 13 screening tests; PRDL aims to participate in procurement for 9 tests aligned with its product portfolio.
Summary: - EMMI (PT Esa Medika Mandiri Tbk) set the IPO price range at Rp446–Rp515 per share, aiming to raise up to Rp269.27 billion to fund debt repayment and business expansion. - IPO timeline: bookbuilding 22–24 June 2026; public offering 2–6 July 2026; allocation and distribution on 6–7 July 2026; effective listing target is 8 July 2026. - Shares offered: up to 522.85 million new shares to the public. - Use of proceeds: - Rp50 billion for partial debt repayment - ~11.8% for expansion/capital expenditure (construction of Cikupa plant) - Up to 68.7% for working capital (procurement, raw materials, inventories) - If IPO proceeds are insufficient, use internal cash or external financing (banks/other institutions) - Underwriters: PT BRI Danareksa Sekuritas and PT INA Sekuritas Indonesia (full commitment). - Financial snapshot (as of 31 Dec 2025): - Total assets: Rp564.44 billion; liabilities: Rp419.42 billion; equity: Rp145.01 billion - Net sales: Rp454.64 billion (2025) - Cost of goods sold: Rp291.21 billion; gross profit: Rp163.21 billion - Net profit: Rp34.13 billion (2025) — rising from Rp0.94 billion (2023) and Rp11.01 billion (2024) - Business context: Indonesian pharma sector IPO; ticker code EMMI.
Ringkasan: - Eskalasi IPO: Esa Medika Mandiri Tbk (EMMI) menawarkan hingga 522,86 juta saham baru, sekitar 30% modal ditempatkan dan disetor penuh. - Harga penawaran: Rp446–Rp515 per saham; potensi dana maksimal sekitar Rp269,27 miliar. - Alokasi saham: 10% (maksimal 52,29 juta saham) untuk program Employee Stock Allocation (ESA). - Penggunaan dana: memperkuat struktur permodalan dan mendukung ekspansi usaha; rincian penggunaannya: sekitar Rp50 miliar untuk sebagian pokok utang, sekitar 11,8% untuk belanja modal pembangunan pabrik di Cikupa, sekitar 68,7% untuk modal kerja. - Dividen: rencana membayar dividen tunai mulai buku 2027 dengan rasio hingga 30% dari laba bersih; realisasi akan mempertimbangkan laba, arus kas, kebutuhan modal kerja, belanja modal, dan rencana investasi. - Kinerja 2025: penjualan bersih naik 18,11% YoY menjadi Rp454,64 miliar; laba bersih naik 209,99% YoY menjadi Rp34,13 miliar. - Struktur keuangan: rasio liabilitas jangka panjang terhadap ekuitas meningkat membaik menjadi 0,74x di 2025 (lebih baik dari 1,17x di 2024 dan 1,28x di 2023). - Jadwal IPO: penawaran awal 22–24 Juni 2026; penawaran umum 2–6 Juli 2026; pencatatan di BEI 8 Juli 2026. - Penjamin pelaksana emisi: BRI Danareksa Sekuritas dan INA Sekuritas Indonesia.
Esa Medika Mandiri Tbk (EMMI) akan melakukan IPO di IDX dengan kode saham EMMI, efektif dicatat pada 8 Juli 2026. Proses bookbuilding berlangsung 22–24 Juni 2026, penawaran umum 2–6 Juli 2026, dengan penjatahan 6 Juli dan distribusi 7 Juli 2026. Rincian IPO - Jumlah saham baru yang ditawarkan: hingga 522,85 juta saham - Harga penawaran: Rp446–Rp515 per saham - Target dana publik: sekitar Rp269,27 miliar Penggunaan dana IPO - Rp50 miliar untuk pembayaran sebagian pokok pinjaman - Sekitar 11,8% untuk pengembangan usaha via pembiayaan belanja modal (pembangunan gedung pabrik Cikupa) - Sekitar 68,7% untuk modal kerja (pembelian barang terkait proyek, bahan baku/persediaan) - Jika dana IPO tidak cukup, perusahaan bisa pakai kas internal atau sumber pembiayaan eksternal (bank/finansial) Penjamin pelaksana emisi (underwriter) - PT BRI Danareksa Sekuritas - PT INA Sekuritas Indonesia - Dengan skema full commitment Kondisi keuangan EMMI (per 31 Desember 2025) - Aset: Rp564,44 miliar - Liabilitas: Rp419,42 miliar - Ekuitas: Rp145,01 miliar - Penjualan bersih 2025: Rp454,64 miliar - Laba kotor 2025: Rp163,21 miliar (beban pokok penjualan Rp291,21 miliar) - Laba bersih: Rp34,13 miliar (pertumbuhan positif: Rp0,939 juta pada 2023 → Rp11,01 miliar 2024 → Rp34,13 miliar 2025)
Summary: - Company: PT Esa Medika Mandiri Tbk (EMMI), a wholesaler of laboratory, pharmaceutical, and medical devices for humans. - IPO plan: EMMI to offer 522.857 million shares (30% of post-IPO capital) via a public offering, with nominal value Rp50 per share. - IPO timeline: - Book building: June 22–24, 2026 - OJK effective statement: June 30, 2026 - Allotment and electronic distribution: July 6–7, 2026 - Listing on BEI: July 8, 2026 - Fundraise target: Maximum Rp269.27 billion, with price range Rp446–Rp515 per share. - Employee Stock Allocation: Up to 52.285 million shares (up to 10% of IPO shares) allocated to employees. - Use of proceeds: - Rp50 billion to repay part of company debt - ~11.8% for capital expenditure (factory building in Cikupa) - ~68.7% for working capital - 2024–2025 performance: - Net sales (2025): Rp454.64 billion, up from Rp384.93 billion (2024) – +18.11% - Operating profit (2025): Rp66.84 billion, up from Rp40.60 billion (2024) – +64.63% - Net profit attributable to owners (2025): Rp34.13 billion (Rp27.98 per share), up from Rp11.01 billion (Rp9.02 per share in 2024) – ~210% increase - Balance sheet (as of Dec 31, 2025 vs 2024): - Total assets: Rp564.43 billion, down from Rp714.39 billion (−21.0%) - Total liabilities: Rp419.42 billion, down from Rp641.01 billion (−34.6%) - Shareholders’ equity: Rp145.01 billion, up from Rp73.37 billion ( +97.6%) Key takeaway: EMMI is pursuing a 30% IPO to raise up to Rp269.27 billion (price Rp446–Rp515), with substantial emphasis on debt repayment and working capital, supported by strong 2025 earnings growth and a stronger equity position despite a lower asset base. Listing planned on BEI on July 8, 2026.
Data sudah sangat lengkap. Sekarang saya hitung semua valuasi dan scoring. Mari saya susun analisis komprehensif.
Berdasarkan data yang sudah diverifikasi dari web search, berikut analisis IPO head-to-head untuk PRDL, JELI, JECX, dan EMMI yang akan listing Juli 2026.
Tanggal analisis: 22 Juni 2026 — Data diverifikasi dari prospektus, Bisnis.com, Kontan, Kompas, DealStreetAsia, IDNFinancials, dan e-ipo.co.id.
| Kode | Harga IPO (Rp) | Jumlah Saham | % Free Float | Target Dana (Rp) | Underwriter | PER (x) | PBV (x) | Margin Bersih | Skor Total | Rekomendasi |
|---|---|---|---|---|---|---|---|---|---|---|
| PRDL | 100–120 | 522,9 jt | ~30% | ~62,74 M | Sucor Sekuritas | 10,2–12,3x | 2,0–2,5x | 22,8% | 64/100 | 🔵 Subscribe |
| JELI | 900–1.120 | 350 jt | ~25,9% | 315–392 M | Sucor Sekuritas | 22,8–28,4x | 4,0–5,0x | 5,2% | 48/100 | 🟡 Wait & See |
| JECX | 1.200–1.400 | 487,9 jt | ~12%* | ~683 M | Trimegah Sekuritas | 20,9–24,4x | 3,1–3,6x | 7,6% | 71/100 | 🟢 Subscribe Kuat |
| EMMI | 446–515 | 522,9 jt | ~27% | ~269,27 M | BRI Danareksa & INA Sekuritas | 19,6–22,6x | 3,6–4,2x | 7,5% | 55/100 | 🟡 Wait & See |
\JECX: 10% saham baru + 2% divestasi dari pemegang saham = ±12% free float. Angka final menunggu prospektus resmi.*
Tesis investasi: Perusahaan alat diagnostik in-vitro (IVD) dengan pertumbuhan pendapatan 27% yoy dan laba bersih melonjak 70% di FY2025 — tapi lebih dari setengah dana IPO dipakai buat bayar utang, bukan ekspansi. Valuasi murah (PER 10–12x) jadi daya tarik utama, sinyalnya: ini "value play" bukan "growth story" murni.
| Kriteria | Bobot | Skor (1-5) | Nilai |
|---|---|---|---|
| Valuasi vs peers | 25% | 4 | 10,0 |
| Pertumbuhan & profitabilitas | 20% | 3 | 6,0 |
| Kualitas penggunaan dana | 15% | 2 | 3,0 |
| Kesehatan fundamental & neraca | 15% | 4 | 6,0 |
| Free float & likuiditas | 10% | 4 | 4,0 |
| Rekam jejak underwriter | 15% | 4 | 6,0 |
| Skor Total Tertimbang | 100% | 64 |
✅ 3 alasan utama membeli:
⚠️ 3 risiko utama:
Verdict: Value play menarik dengan PER sangat rendah — Subscribe untuk yang paham hold, tapi jangan harap ARA gila-gilaan.
Tesis investasi: Raja jeli dan nata de coco dengan market share dominan (~50%), tapi pendapatan turun 3 tahun berturut-turut. Lonjakan laba 219% didorong efisiensi — bukan pertumbuhan volume. Valuasi PER 23–28x di atas MYOR (11x) dan ICBP (9x) — premium yang tidak masuk akal untuk bisnis dengan pendapatan menyusut.
| Kriteria | Bobot | Skor (1-5) | Nilai |
|---|---|---|---|
| Valuasi vs peers | 25% | 1 | 2,5 |
| Pertumbuhan & profitabilitas | 20% | 2 | 4,0 |
| Kualitas penggunaan dana | 15% | 4 | 6,0 |
| Kesehatan fundamental & neraca | 15% | 2 | 3,0 |
| Free float & likuiditas | 10% | 3 | 3,0 |
| Rekam jejak underwriter | 15% | 4 | 6,0 |
| Skor Total Tertimbang | 100% | 48 |
✅ 3 alasan utama membeli:
⚠️ 3 risiko utama:
Verdict: Merek kuat tapi fundamental dan valuasi tidak saling mendukung — Wait & See sampai harga final turun signifikan.
Tesis investasi: Jaringan rumah sakit mata premium dengan 5 RS dan 11 klinik, pertumbuhan pendapatan stabil 10% per tahun, laba bersih Rp73,8 M di FY2025. Valuasi PER 21–24x sebanding dengan rumah sakit sejenis (SILO 27x, MIKA 30x+). Underwriter tunggal Trimegah Sekuritas — reputasi solid. Ini kandidat paling kuat dari segi kualitas bisnis.
| Kriteria | Bobot | Skor (1-5) | Nilai |
|---|---|---|---|
| Valuasi vs peers | 25% | 4 | 10,0 |
| Pertumbuhan & profitabilitas | 20% | 3 | 6,0 |
| Kualitas penggunaan dana | 15% | 3 | 4,5 |
| Kesehatan fundamental & neraca | 15% | 3 | 4,5 |
| Free float & likuiditas | 10% | 2 | 2,0 |
| Rekam jejak underwriter | 15% | 4 | 6,0 |
| Skor Total Tertimbang | 100% | 71 |
✅ 3 alasan utama membeli:
⚠️ 3 risiko utama:
Verdict: Kualitas bisnis terbaik di antara keempatnya — Subscribe Kuat apalagi kalau harga final di bawah Rp1.300.
Tesis investasi: Distributor alat kesehatan dengan pertumbuhan laba eksplosif (+210% yoy), didorong proyek tender pemerintah (98,5% pendapatan dari pemerintah). Tapi — hampir 70% dana IPO cuma untuk modal kerja, bukan investasi produktif. Ketergantungan pada tender IsDB dan World Bank bikin pendapatan tidak stabil.
| Kriteria | Bobot | Skor (1-5) | Nilai |
|---|---|---|---|
| Valuasi vs peers | 25% | 3 | 7,5 |
| Pertumbuhan & profitabilitas | 20% | 3 | 6,0 |
| Kualitas penggunaan dana | 15% | 2 | 3,0 |
| Kesehatan fundamental & neraca | 15% | 2 | 3,0 |
| Free float & likuiditas | 10% | 3 | 3,0 |
| Rekam jejak underwriter | 15% | 3 | 4,5 |
| Skor Total Tertimbang | 100% | 55 |
✅ 3 alasan utama membeli:
⚠️ 3 risiko utama:
Verdict: Laba tumbuh cepat tapi kualitas bisnis dipertanyakan — Wait & See untuk jangka panjang, mungkin menarik untuk flip.
| # | Emiten | Skor | Label | Alasan | |:-:|:------:|:----:|:-----:|--------| | 1 | JECX | 71 | 🟢 Subscribe Kuat | Bisnis premium, pertumbuhan stabil, valuasi wajar vs peers RS | | 2 | PRDL | 64 | 🔵 Subscribe | Value play dengan PER paling murah, net margin tertinggi | | 3 | EMMI | 55 | 🟡 Wait & See | Laba tumbuh tapi risiko konsentrasi pemerintah ekstrem | | 4 | JELI | 48 | 🟡 Wait & See | Valuasi premium tidak sebanding pendapatan turun |
Trader jangka pendek (flipping di hari listing):
Investor jangka panjang (hold):
Jika hanya boleh pilih 1 dari 4: JECX — kombinasi kualitas bisnis, prospek pertumbuhan, dan potensi ARA paling seimbang.
Jika pilih 2 dari 4: JECX + PRDL — JECX untuk kualitas dan momentum listing + PRDL untuk value play murah dengan margin gemuk.
Hindari JELI pada harga bookbuilding saat ini. Kalau harga final turun ke Rp700–800, baru masuk radar.
Analisis ini bersifat edukatif dan informasional, bukan ajakan untuk membeli atau menjual saham. Seluruh keputusan investasi dan risikonya sepenuhnya berada di tangan investor masing-masing. Wajib membaca prospektus resmi di e-ipo.co.id dan keterbukaan informasi BEI sebelum mengambil keputusan. Harga IPO dan performa masa lalu tidak menjamin keuntungan di masa depan. Penulis dan platform tidak bertanggung jawab atas kerugian investasi yang timbul.
Track whales and shadow smart trades
Check out whales, what they are buying, selling and get an edge on your trades
Smart Money